Dr. Vaccaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9135 SW Barnes Rd
Ste 261
Portland, OR 97225Phone+1 503-216-6300Fax+1 971-828-0118
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004- Duke University HospitalResidency, Internal Medicine, 1998 - 2001
Louisiana State University School of Medicine in New OrleansClass of 1998
Certifications & Licensure
TN State Medical License 2023 - 2026
NC State Medical License 1998 - 2025
OR State Medical License 2008 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Portland Monthly Magazine Castle Connolly, 2011
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
- Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Start of enrollment: 2015 Jul 20
- Join now to see all
Publications & Presentations
PubMed
- 115 citationsEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Ra...Matthew H G Katz, Qian Shi, Jeff Meyers, Joseph M Herman, Michael Chuong
JAMA Oncology. 2022-09-01 - 822 citationsPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi
The Lancet. Oncology. 2020-05-01 - 1594 citationsPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
The Lancet. Oncology. 2018-07-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
